Abstract
Background Recent increase in human infections of highly pathogenic avian influenza H5N6 virus and its high mortality have raised concerns.
Methods To analyze evolution of outcomes, longitudinal clinical data and specimens were collected from five patients infected with H5N6 virus after admission. All patients received antiviral treatment either sequentially or in combination of oseltamivir with baloxavir. Severity of illness, and viral load in sputum, urine and blood, and cytokine levels in serum and sputum were serially analyzed.
Results When delayed oseltamivir showed poor effects on high respiratory viral load, baloxavir was prescribed and viral load had a rapid reduction. All patients developed acute respiratory distress syndrome (ARDS) and sepsis within one week after disease onset, three patients died eventually. Nonsurvivors had more severe preexisting condition, extrapulmonary organ dysfunction and insufficient H5N6 virus-specific antibody response. Grouped by delta SOFA on the sample collection date, serum levels of IL-1α, IL-1β, IL-1RA, MIF, Mig, MIP-1α, IFN-γ, IL-12p40, IL-16, IL-18, IL-2Rα, IL-6, basic FGF, G-CSF, HGF, M-CSF, SCF were identified as indicator cytokines reflecting sepsis progression; and sputum levels of IL-18, IL-6, HGF, M-CSF were indicators of ARDS progression. Comparisons of cytokine levels before, during and after baloxavir treatment suggested that, baloxavir may also reduce a few indicator cytokines in sputum and serum that related to viral load and multi-organ dysfunction.
Conclusions Baloxavir can effectively reduce viral load and few proinflammatory cytokines associated with deterioration. However, disease outcome is determined by severity of preexisting conditions and multi-organ dysfunction.
Highlights
(1) Baloxavir potently decreased viral load in avian influenza H5N6 human infections.
(2) Preexisting conditions, extrapulmonary dysfunction and systemic inflammation determined prognosis of H5N6 patients.
(3) Indicator cytokines in sputum and serum reflecting ARDS and sepsis progression respectively, were identified in H5N6 patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Natural Science Foundation of China (grant number 81761128014). Z.Y. received support from Guangzhou Institute of Respiratory Health Open Project (funds provided by China Evergrande Group, grant number 2020GIRHHMS01) and Zhongnanshan Medical Foundation of Guangdong Province (grant number ZNSA-2020013). W.G. reported funding from Guangzhou Science and Technology Program (grant number 202102100003), Open Project of State Key Laboratory of Respiratory Disease (grant number SKLRD-OP-202001) and Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases Funding Project (grant number GHMJLRID-Z-202105). W.P. received support from the National Natural Science Foundation of China (grant number 31970884). L.S. and H.Z. reported funding from Guangdong Basic and Applied Basic Research Foundation (grant number 2020B1515120045 and 2020A1515110151).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by ethical committees of The First Affiliated Hospital of Guangzhou Medical University (Ethics No. 2016-78). Written consents have been signed by the patients or their family members for collecting samples and clinical data for this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author for backup contact before publication, Weiqi Pan, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou, Guangdong, 510120, China., Tel: 8620-83205181; Fax: 8620-83205181; E-mail: panweiqi{at}gird.cn
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding authors.
